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 ABSTRACT
The mammalian Endosomal Sorting Complex Required for Transport 
(ESCRT) pathway mediates the final membrane fission step of cytokinesis, 
known as abscission. Prior to abscission, the ESCRT machinery is recruited to 
the intercellular bridge that connects nascent daughter cells. Once there, 
subunits of the ESCRT-III complex bind the plasma membrane and oligomerize
into membrane-bound filaments.  These filaments constrict the membrane, 
resulting in membrane fission and release of two independent daughter cells.
Here, I describe the creation of siRNA/shRNA depletion and rescue 
assays for testing abscission functions of the ESCRT-III proteins IST1 and 
CHMP2A. siRNA or shRNA treatments were used to deplete endogenous IST1 
or CHMP2A protein levels, and exogenous wild-type or mutant constructs were 
tested for their ability to “rescue” the resulting abscission defects, as assayed by 
flow cytometry or morphological assays.  These assays confirmed that both IST1 
and CHMP2A are required for abscission, and that exogenous wild-type IST1 
and CHMP2A can rescue the defects induced by depletion of the cognate 
proteins.  
The IST1 and CHMP2A depletion/rescue assays provided a means for 
testing whether different IST1 and CHMP2A mutants can function in abscission. 
As an initial proof of principle, I tested whether mutations in conserved basic
 patches in the N-terminal alpha helix inhibit the ability of IST1 and CHMP2A to 
function in abscission. Tests were performed because previous studies had 
implicated these basic patches in ESCRT-III membrane binding.  Consistent with 
this hypothesis, mutations in the basic residues of IST1 abolished abscission 
functions; however, the CHMP2A data were ambiguous.  Thus, my work has 
confirmed that the ESCRT-III proteins IST1 and CHMP2A are both required for 
the abscission step of cytokinesis, and have provided an assay system that can 
be used to test the functionality of mutant proteins.  
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Overview of the ESCRT Pathway
The Endosomal Sorting Complexes Required for Transport (ESCRT) 
pathway mediates membrane fission events in a variety of cellular processes 
including: multivesicular bodies (MVB) vesicle formation, shedding microvesicle 
formation, exosome formation, and abscission (the final membrane fission event
in cytokinesis)1. This pathway is also required for the budding of enveloped 
viruses such as HIV, arenaviruses, filoviruses, paramyxoviruses, orbiviruses, and 
rhabdoviruses2,3,4. 
These are all “reverse topology” membrane fission events in which the 
membrane is constricted towards the cytoplasm by ESCRT proteins that act 
within the membrane tube where fission will take place (Fig. 1.1). Conversely, in
“normal topology” membrane fission events, the membrane is constricted 
towards the extracellular space by proteins that act from the outside of the 
membrane tube (e.g., as in endocytosis and COP-I and COP-II-mediated vesicle 
formation; Fig. 1.1) 5,6.  
The ESCRT pathway was discovered through yeast genetic screens 
designed to identify proteins required for proper vacuole protein sorting (vps)7.
The yeast vacuole (lysosome in animal cells) plays a central role in a series in 
physiological processes such as osmoregulation, amino acid storage, and protein 
degradation1,7.  Membrane proteins targeted for degradation are typically first 
sorted into vesicles that bud into the lumen of MVBs1.  These proteins are 
delivered for degradation when the MVB fuses with the vacuole.  The original
yeast vacuole protein sorting mutant strains were divided into six classes 
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(classes A–F) based on the morphologies of their vacuoles8.  The class E vps
mutants were subsequently further divided into five multiprotein complexes 
termed ESCRT-0, -I, -II, -III, and Vps49,10,11,12. ESCRT-0 is now considered to be 
an endosome-specific ESCRT adaptor, and the ESCRT-I, -II, -III, and VPS4 




Recruitment of the ESCRT Pathway
The core complexes of the ESCRT pathway are recruited sequentially to 
sites of membrane fission. ESCRT pathway recruitment can be subdivided into 
three stages: first, adaptor proteins like ESCRT-0 mark a future site of membrane 
fission; second, early-acting ESCRT factors ALIX, ESCRT-I, and ESCRT-II arrive 
and stabilize the vesicle neck; third, the late-acting ESCRT factors ESCRT-III
and VPS4 arrive and catalyze membrane fission. Each of these different stages 
is discussed below in greater detail.   
Process-specific adaptor proteins initiate ESCRT recruitment to different 
sites of action.  Examples of adaptor proteins include: ESCRT-0 (e.g.,
HRS:STAM and related endosomal adaptors, MVB formation), ARRDC1 
(shedding microvesicle formation), Gag (retrovirus budding), and CEP55 
(abscission)13,14,15,16,17,18. Adaptor proteins are localized to their specific sites of 
action through adaptor:membrane and adaptor:protein interactions19,20.  
The early-acting factors of the ESCRT pathway are then recruited to a site
of action by direct binding to process-specific adaptor proteins.  The early-acting
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ESCRT factors include: the ESCRT-I/ESCRT-II supercomplex, and Bro1 protein 
family members (i.e., proteins such as ALIX that contain a Bro1 domain)2. 
The late-acting factors of the ESCRT pathway, ESCRT-III and VPS4, bind
directly to the early-acting factors2. Unlike the other discrete ESCRT complexes, 
subunits of the ESCRT-III complex do not bind one another until they 
coassemble on the membrane with the exception of IST1 and CHMP1B, which 
form a binary complex in yeast21,22,23. Humans express a total of 12 ESCRT-III 
proteins that comprise 8 families (termed Charged Multivesicular Body Proteins) 
CHMP1–7 and Increased Sodium Tolerance 1 (IST1), with three different 
CHMP4 proteins (A, B, and C) and two different CHMP1 (A, B) and CHMP2 (A,
B) proteins; Fig. 1.2a). All ESCRT-III proteins share a conserved core structure 
known as the ESCRT-III fold, which is made up of four alpha helices24,25.  Helices 
one and two form a helical hairpin, and helices three and four pack against the 
open end of the hairpin (Fig. 1.2b).  The ESCRT-I/-II supercomplex binds directly 
to CHMP6, and the Bro domains of Bro1 protein family members such as ALIX,
BROX, and HD-PTP bind directly to CHMP4 and CHMP5 proteins26,27,28,29,30,31.
The different ESCRT-III proteins are thought to copolymerize into membrane-
associated filaments32,33,34,35. The VPS4 ATPase then binds to different sites on 
the exposed C-terminal tails of the polymerized ESCRT-III filaments, thereby 
completing ESCRT factor recruitment36,37,38. VPS4 provides the energy for
ESCRT-III-mediated membrane fission by using ATP hydrolysis to disassemble 




Models for ESCRT-III Mediated Membrane Fission
It is not yet clear how ESCRT-III filaments and VPS4 accomplish 
membrane fission, but three general models have been proposed: the dome 
model, the break and slide model, and the whorl model (Fig. 1.3)42,43,44,45. These 
models all incorporate direct involvement of membrane-bound ESCRT-III
filaments and postulate a role for VPS4.  According to the dome model (Fig.
1.3a), ESCRT-III filaments spiral into a helical dome, which binds and constricts 
to a point43. VPS4 then disassembles the ESCRT-III filaments to recycle their 
constituent subunits. In the break and slide model (Fig. 1.3b, proposed only for 
the abscission step of cytokinesis), ESCRT-III filaments initially form wide helices
approximately one micron away from the eventual membrane fission site42,44.
VPS4 then severs the ESCRT-III helices and the distal part constricts by twisting, 
relocalizes to a narrower site, and then forms a dome that mediates membrane 
fission.  In the whorl model (Fig. 1.3c, proposed to explain MVB vesicle 
formation), multiple ESCRT-I/ESCRT-II supercomplexes deform the membrane 
and stabilize the vesicle neck45. These ESCRT-I/ESCRT-II supercomplexes also 
nucleate the formation of 6–10 ESCRT-III filaments, which then grow into the 
center of the lumen of the vesicle neck forming a “whorl” that draws the 
membrane inward to a fission point.
 
 
The Abscission Step of Cytokinesis
The ESCRT pathway mediates the abscission step of cytokinesis17,46,47.
Cytokinesis begins during the mitotic phase of the cell cycle and progresses 
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through ingression of the cleavage furrow until the nascent daughter cells are 
connected by a narrow membrane tube (the intercellular bridge). The abscission 
event then separates the bridge to produce two discrete daughters.  
The cell cycle is the series of events that ultimately leads to the duplication
of a parent cell to produce two independent daughters (Fig. 1.4). Mitosis is the 
cell cycle phase in which a cell segregates its DNA into the nascent daughters
(Fig. 1.4). During the metaphase stage of mitosis, sister chromosomes attached 
to microtubules align on the equatorial metaphase plate, forming a bipolar 
spindle (Fig. 1.5). The aligned sister chromosomes are then pulled toward the 
poles at the onset of anaphase.  The spindle microtubule organization provides
the spatial and temporal cues for the formation of an equatorial ring of myosin II 
and actin known as a contractile ring (Fig. 1.5)48,49.  Contractile ring formation 
marks the beginning of cytokinesis.  
The contractile ring constricts inward, creating a cleavage furrow (Fig.
1.5). Myosin II motor activity along the actin filaments of the contractile ring 
provides the force required for ingression of the furrow (Fig. 1.5)50. Contraction 
continues until the microtubules are compacted within a narrow intercellular 
bridge that connects the nascent daughter cells51.  At the center of this bridge is
a dark zone (known as a “Flemming Body” or “midbody”), which helps to 
organize the proteins involved in abscission50,51.  
The ESCRT pathway mediates the final membrane fission event of 
abscission by forming cut sites on one or both sides of the midbody. The adaptor 
protein CEP55 is recruited to the midbody of the intercellular bridge by the 
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microtubule interacting protein Centralspindlin19. CEP55 then recruits the early-
acting factors of the ESCRT pathway, ALIX and ESCRT-I, which in turn bind and 
organize ESCRT-III proteins (Fig. 1.6) 18,25,26,28,29,46,52,53,54,55. The ESCRT-III
proteins form membrane-bound filaments and recruit VPS4 to complete
abscission17,25,56,57. If ESCRT pathway recruitment is disrupted, then the cell
arrests at the intercellular bridge stage, and the bridge can eventually coalesce 
back to reform a single, multinucleate cell (termed abscission failure)56. 
Many ESCRT-III Proteins are Required for Abscission
Most of the different human ESCRT-III proteins apparently play a role in 
abscission, although their functions are not fully understood.  Depletion of the 
ESCRT-III proteins IST1, CHMP2A, or CHMP3 produces strong abscission
failure25,56,57. CHMP1A, CHMP2B, CHMP4B, CHMP4C, and CHMP7 are also 
required for efficient abscission, although their depletion can also induce 
upstream mitotic defects56. Thus, depletion studies have established that IST1, 
CHMP2A, and CHMP3 are definitely required for abscission, and that most other 
ESCRT-III proteins probably are as well, although their abscission functions can 
be masked by mitotic defects under some conditions. 
Rescue Assays For Analyses of ESCRT-III
Abscission Functions
SiRNA or shRNA depletion and rescue assays (termed depletion/rescue 
assays) are increasingly used to test the proposed functions of proteins in 
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mammalian cell processes58. In these experiments, endogenous protein levels 
are lowered by siRNA or shRNA treatments, and an siRNA/shRNA-resistant 
exogenous protein is reintroduced and tested for phenotypic rescue. In cases 
where the wild-type, exogenous protein can functionally replace the endogenous 
protein, then mutant exogenous proteins can also be tested for function.  Thus, a 
depletion/rescue assay is a powerful genetic approach for testing the functional 
importance of different protein elements in mammalian cells.
In my thesis research, I developed and tested depletion/rescue assays for 
the ESCRT-III proteins, IST1 and CHMP2A.  In the next chapter, I show that 
exogenous, wild-type IST1 or CHMP2A can functionally replace the abscission 
functions of cognate endogenous IST1 or CHMP2A activities. I show that these 
assays can be used to test the functional importance of conserved basic patches 
on the ESCRT-III core that have been proposed to be the ESCRT-III membrane-
binding surface.  
In the future, I anticipate that analogous IST1 and CHMP2A
depletion/rescue assays will allow researchers to dissect other mechanistic 
details of ESCRT-III function in abscission. Details of interest include: the 
structure of ESCRT-III monomers within ESCRT-III filaments and the 
protein:protein interactions within the membrane-bound filaments.
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Figure 1.1: Membrane fission topologies. In “normal topology” membrane 
fission events such as endocytosis, the fission machinery (depicted 
schematically in red) is located on the outside of the vesicle neck and 
constricts the membrane towards the extracellular space.  In “reverse 
topology” membrane fission events such as enveloped virus budding, the 
fission machinery (depicted schematically in green) is located within the bud 
neck and constricts the membrane towards the cytoplasm
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Figure 1.2: ESCRT-III proteins and the core ESCRT-III fold. (A) The 8 
human ESCRT-III protein families.  The names of the 12 human ESCRT-III
proteins are given at the left and schematic illustrations of their constituent 
helices and factor binding sites are given at the right.  Abbreviations: MIM1 
(Type 1 MIT Interaction Motif), a VPS4 binding site; MIM2 (Type 2 MIT 
Interaction Motif), a VPS4 binding site; ALIX, ALIX protein binding site.  
Colored boxes denote helices.  (B) Schematic diagram of the core ESCRT-III
fold.  Alpha helix 1 and alpha helix 2 form an extended hairpin and helices 3 
and 4 pack against the open end of the hairpin.  The color coding of the core 
helices matches that in part (A). 
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Figure 1.3: Models for ESCRT-mediated membrane fission. (A) Image 
representing the “dome model.”  1) ESCRT-III filaments form helices at the 
base of the bud neck.  2) ESCRT-III filaments form constricting spirals that 
draw the associated membrane inward.  3) Membrane fission occurs at the 
apex of the ESCRT-III dome, and VPS4 (blue star) disassembles the ESCRT-
III filaments.  (B) Image representing the “break and slide model.”  1) ESCRT-III 
filaments form helices at the base that initially have a wider diameter than the 
ground state helix.  2) VPS4 severs the ESCRT-III helices, which then constrict 
and localize to a narrower membrane site.  3) The relocalized ESCRT-III helix 
forms a dome that mediates membrane fission.  VPS4 then disassembles the 
ESCRT-III filaments.  (C) Image representing the “whorl model.”  1) Multiple 
copies of the ESCRT-I and -II supercomplex localize to the bud neck (red 
circle).  2) The ESCRT-I and -II supercomplexes nucleate ESCRT-III filaments 
that grow toward the center of the bud neck.  3) The ESCRT-III filaments form 
a whorl pulling the membrane inward toward a fission point.  VPS4 may be 




Figure 1.4: Overview of the cell cycle. In interphase, the cell duplicates its 
DNA, performs its cellular functions, and prepares for mitosis.  In the mitotic 
phase, a cell segregates the sister chromatids to nascent daughter cells.  In 




Figure 1.5: The timing and progression of cytokinesis. Between the 
start of metaphase and the end of anaphase the spindle microtubule 
organization provides the spatial and temporal cues necessary for 
formation of an equatorial contractile ring.  The contractile ring ingresses 
to form a cleavage furrow during telophase and ultimately compacts the 
microtubules into a narrow intercellular bridge.  Abscission then occurs 
producing two daughter cells. 
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Figure 1.6: Organization of the ESCRT pathway during abscission. The
adaptor protein, CEP55 (green), localizes to either edge of the midbody.  
CEP55 binds ALIX (purple) or the TSG101 subunit of ESCRT-I (pink) using a 
noncanonical coiled coil domain known as the ESCRT- and ALIX-binding 
region (EABR).  The left half of the figure shows how ALIX then binds the C-
terminal tail of CHMP4 (orange), which in turn interacts with other ESCRT-III
proteins (yellow). The right half of the figure shows that ESCRT-I can form a 
super complex with ESCRT-II (teal).  ESCRT-II binds the ESCRT-III protein 
CHMP6 (orange), which can bind CHMP4 proteins, leading to recruitment of 
other ESCRT-III proteins. The PDB accession numbers of the structures used 
to make this figure: 2OEV (ALIX), 2P22 (ESCRT-I), 1S1Q (TSG101 UEV), 
2J9U (VPS28p CTD), 2ZME (ESCRT-II core), 2HTH (EAP45 GLUE domain), 
3E1R (CEP55 EABR bound to PRR), and 2GD5 (CHMP3 used to represent 
the CHMP5 and CHMP4 cores).  A CHMP2A homology model created using 
the PHYRE protein fold recognition server (http://www.sbg.bio.ic.ac.uk/













The ESCRT pathway mediates “reverse topology” membrane fission 
events in a series of different cellular and viral processes including: enveloped 
virus budding, MVB vesicle formation, shedding microvesicle formation, exosome 
formation, and abscission (the final membrane fission event in cytokinesis)2. The 
ESCRT-I, -II, -III, VPS4 complexes, and Bro1 family proteins make up the core 
machinery of the ESCRT pathway. Fission is apparently affected by membrane-
bound ESCRT-III filaments, which deform the membrane towards the cytoplasm 
(“reverse topology”) ultimately leading to fission32,33,34,59,60,61.  However, the 
mechanistic details of this process are unknown. 
In this chapter, I describe the development and validation of 
depletion/rescue assays for IST1 and CHMP2A in abscission.  These assays 
confirm that IST1 and CHMP2A are required in abscission. I also applied these 
assays to demonstrate the functional importance in abscission of basic patches 
on the N-terminal alpha helix of IST1 and CHMP2A.  Thus, the IST1 and 
CHMP2A depletion/rescue assays can be used to test the functionality of mutant 
IST1 and CHMP2A proteins.
Rationale for IST1 studies
I chose IST1 as a target for depletion/rescue assay development for four
reasons.  First, IST1 is a strong effector of abscission; second, IST1 is likely 
directly involved in abscission; third, a high-resolution crystal structure of IST1 is 
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available, and electron microscopy (EM) reconstructions of IST1-containing 
filaments are forthcoming; and fourth, IST1 oliogmers can deform membranes in 
vitro, but the mechanisms underlying membrane constriction and fission by 
ESCRT-III filaments are not yet well understood.
Depletion of IST1 from HeLa cells induces abscission failure (an increase 
in the number of cells with an intercellular bridge and multinucleate cells as 
compared to a wild-type control), and the phenotype has a higher penetrance 
than the defects induced by depletion of other ESCRT-III proteins25,56,57.  Thus, 
IST1 is a strong effector of abscission.  A direct role for IST1 in abscission is 
supported by the observation that IST1 localizes to the intercellular bridge during 
cytokinesis. As shown in Fig. 2.1a, confocal fluorescence microscopy images of 
HeLa cells stained with an anti-IST1 antibody show strong IST1 localization (red) 
to the intercellular bridge during cytokinesis25,57. Super-resolution IST1 
fluorescence images reveal that IST1 initially organizes into two rings, one on 
either side of the midbody (Fig. 2.1b upper panels).  One or both of the rings then
extrude and constrict to form continuous cones that narrow to the point of 
membrane fission (Fig. 2.1b lower panels).  Thus, IST1 localizes to the 
intercellular bridge and forms structures that could constrict the plasma 
membrane to a fission point.  
  A high-resolution IST1 crystal structure and forthcoming IST1 filament 
structural studies make IST1 an attractive target for further functional 
characterization. The 1.8 angstrom resolution IST1 N-terminal domain (IST1NTD,
residues 1–189) crystal structure provides a detailed view of the core IST1 
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structural elements23.  IST1NTD forms filaments in vitro, and ongoing studies are 
attempting to reconstruct the structure of the IST1NTD:CHMP1B copolymer by EM
(A. Frost and J. McCullough, personal communication)23.  IST1 filaments can 
also deform lipid bilayers in vitro. As shown in Fig. 2.2A, purified IST1NTD
filaments can organize into helical tubes that can extrude from the lumens of 
liposomes.  These tubes appear to be capped by a “dome” of IST1NTD protein
(Fig. 2.2a–c). Under these same conditions, IST1NTD filaments can also form
spirals and/or concentric circles (Fig. 2.2d, e).  These observations demonstrate
that IST1 filaments can bind and deform lipids, and that the IST1 assemblies can 
narrow to form a dome providing a possible mechanistic explanation for IST1 
function in abscission. 
Rationale for CHMP2A studies
To extend my IST1 studies to other ESCRT-III proteins, I also developed a
CHMP2A depletion/rescue assay.  I chose CHMP2A because this protein, like 
IST1, is a strong effector of abscission, is likely directly involved in abscission, 
and because CHMP2A can form filaments and tubes in vitro.  
SiRNA depletion experiments have established that CHMP2A is also 
required for abscission in HeLa cells56.  The severity of the abscission failure
induced by CHMP2A depletion is again greater than the defects induced by 
depletion of other ESCRT-III proteins, implying that CHMP2A is another strong 
abscission effector56. CHMP2A also forms rings and cones within the 
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intercellular bridge during cytokinesis. Thus, CHMP2A is also likely directly 
involved in abscission. 
Finally, when co-incubated with CHMP3, CHMP2A lacking its C-terminus 
(CHMP2A, residues 1-150) oilogmerizes into filaments, which wind up into
helical tubes32,33.  The similarities between CHMP2A and 
IST1NTD:CHMP1B helical tubes suggests that CHMP2A and IST1 may perform 
analogous functions in abscission.  
Validating the IST1 and CHMP2A rescue assays
 Depletion/rescue experiments have proven to be a powerful approach for 
genetic analyses of protein functions in human cells58. These assays have two 
parts.  First, siRNA/shRNA depletion of an endogenous protein must be shown to 
have a measureable phenotype.  Second, reintroduction of the exogenous 
protein from an siRNA/shRNA resistant expression construct must be shown to 
rescue the phenotype.  In this study, I demonstrate that silencing of either 
endogenous IST1 or CHMP2A results in strong abscission failure, and that 
reintroduction of exogenous IST1 and CHMP2A rescues the cognate phenotype. 
Testing a model for ESCRT-III membrane binding  
The crystal structure of CHMP3 revealed a large patch of basic residues 
on the first alpha helix that faces away from the core ESCRT-III domain24.
Weissenhorn and colleagues have proposed that this conserved basic patch
constitutes a phospholipid membrane binding surface24. Support for their model 
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comes from studies of CHMP3 membrane binding in enveloped virus budding.
Specifically, they found that overexpressing GFP-PK-CHMP3	
GFP-pyruvate 
kinase chimera, residues 1–150 of CHMP3) dominantly inhibited HIV-1 budding 
and resulted in accumulation of the CHMP3 fusion protein at the plasma 
membrane24.  However, a mutant GFP-PK-CHMP3	
			
R32A, and R35S) protein that lacked the basic patch failed to accumulate at the 
plasma membrane or to inhibit HIV-1 budding 24.  These results support a model 
in which the basic patch on the first alpha helix of ESCRT-III proteins mediates 
membrane binding.  However, this model has not been rigorously tested, 
particularly in abscission. 
I therefore performed depletion/rescue experiments, both to test the 
membrane binding model proposed by Weissenhorn and to confirm that my 
depletion/rescue assays can be used to test the functionality of IST1 and 
CHMP2A mutants in abscission24. To perform these studies, I generated 
siRNA/shRNA resistant constructs that expressed mutant IST1 and CHMP2A 
proteins lacking the basic patches and tested their ability to rescue abscission 
failure induced by depletion of the endogenous proteins.   
Materials and Methods
Cell cultures
HeLa and 293T cells were grown in complete media (DMEM 
supplemented with 10% FBS and 2 mM L-glutamine) at 37º C with 5% CO2.  
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PEI transfections  
Prior to transfection, 293T cells were seeded at an initial density of 2x106 
cells/well in a 10 cm dish and allowed to grow for 24 h.  Polyethylenimine (PEI, 
Polysciences 24765, final concentration of 0.82 µg/µl) was added along with 
DNA (12–15 µg) to 0.5 ml of complete media, and the solution was mixed by 
inverting the tube that was allowed to stand for 10 min at room temperature. The 
mixture was then added drop wise to the previously seeded 293T cells.  The
media was changed 12 h posttransfection, and the cells were harvested at the 
designated time points.
Expression vectors
ESCRT-III, HIV, MuLV, and control expression vectors used in this study 
are listed in Table 2.1.
Mutagenesis
The mutant YFP-IST1 3M construct (which expresses an IST1 protein with 
the following mutations: R16E, R27E, and K38E) was generated by replacing the 
SacI/AflII restriction digest fragment of the parental YFP-IST1 expression vector 
with a synthetic oligonucleotide that encoded the mutations.  
The CHMP2A 3M construct was generated using a splicing by overlap 
extension PCR reaction (SOEing PCR). Briefly, a synthetic oligonucleotide
matching the N-terminal end of CHMP2A (containing the following mutations: 
R16E, R27E, and K42) was amplified by PCR to create a mutant, N-terminal 
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CHMP2A PCR fragment.  A C-terminal CHMP2A PCR fragment that contained 
the siRNA resistance mutations was also amplified by PCR.  These N- and C-
terminal PCR products were mixed with synthetic oligonucleotides that amplified 
full-length CHMP2A in a SOEing PCR reaction, resulting in full-length, mutant 
CHMP2A PCR product.  This was then cloned into the pU6-CMV vector by 
AgeI/EcoRI restriction digest and ligation.  
Cell lines
HeLa cells that stably expressed YFP-IST1 or YFP-IST1 3M were 
generated using an MuLV-based transduction system56. To create the 
transduction vector, the pQCXIN_YFP-IST1 or pQCXIN_YFP-IST1-3M (5 µg) 
expression vector was cotransfected into 293T cells (seeded at 2x106 24 h
earlier) with the mammalian expression vector pGag-Pol (5 µg) and the VSV-G
expression vector pMD.G (2 µg). The media was changed 12 h posttransfection. 
36 h posttransfection, the vector-containing supernatant was collected in 1 ml 
aliquots, filtered (0.45 µm filter), frozen, and stored at 80º C.
HeLa cells to be transduced were seeded (initial density of ~2x105 
cells/well) in a 6-well plate and incubated with a 1:1 mixture of 1 ml of vector-
containing supernatant and 1ml fresh media for 12 h, followed by a media 
change and maintenance (1 week).  The cells were maintained for approximately 
1 week after which the YFP-positive cells were collected using the FACSAria Cell 
Sorter (University of Utah Cores), plated, allowed to grow for 2 weeks, harvested 
at 80% confluency, and frozen in conditioned media containing 10% DMSO and 
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52% FBS.  Experiments involving YFP-IST1 or YFP-IST1-3M used cells from 
these frozen aliquots. 
siRNA design and validation
siRNAs used in this study were: CGUACGCGGAAUACUUCGA (CON), 
490AGAUACCUGAUUGAAAUUG509 (IST1-1), and 377CCAAGUAUAGCAAG
GAAUA396 (IST1-2, numbers denote the target site in the sense strand of the 
coding region).  The IST1-1 and CON (control) siRNAs had been validated and 
reported previously25.  The IST1-2 siRNA was designed using the Dharmacon 
siDESIGN center (www.thermo.com/sidesign).  The efficacy of IST1-2 siRNA 
mediated depletion of endogenous HeLa IST1 was validated using anti-IST1
immunoblots and immunofluorescence microscopy in fixed HeLa cells stained 
with anti-IST1 (Fig. 2.3, data not shown).
shRNA design, validation, and delivery and rescue
CHMP2A depletion studies used the following processed shRNAs:
CGUACGCGGAAUACUUCGA (CON) and 395AGGCAGAGATCATGGATAT412
(CHMP2A). This CHMP2A target site was used previously in siRNA depletion 
studies of CHMP2A, and the CON shRNA matches the CON siRNA listed 
above56.
pU6-CMV vectors were used to create HIV-based transduction vectors to 
deliver shRNAs and express shRNA-resistant rescue constructs.  These vectors 
were modified from the parent CSII-CMV-MCS vector (Riken BioResource 
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Center) by Devin Christiansen (Sundquist lab). In this vector, unprocessed RNA 
hairpins are expressed by RNA polymerase III from a U6 promoter.  Rescue 
constructs are expressed from a downstream cytomegalovirus (CMV) promoter, 
and the mCherry transduction marker is expressed from a downstream internal 
ribosome entry site (IRES). Hence, these vectors express both the shRNA and 
the shRNA-resistant rescue construct, ensuring that all transduced cells depleted 
of CHMP2A will also express the exogenous rescue construct.  When 
cotransfected with pCMVdeltaR8.91 (HIV Gag, Pol, and Rev) and (pMD.G VSV-
G envelope) expression vectors, packageable proviral RNA expressed by the 
pU6-CMV is packaged into a pseudotyped HIV virus, creating a transduction 
vector.  
siRNA transfections
HeLa cells (12- or 6-well plates) were transfected with duplex siRNA (final 
concentration of 20 nM) 24 h after seeding (initial density of 3x104 or 2x105
cells/well, respectively) using Lipofectamine RNAi MAX, following the 
manufacturer’s recommendations.  Cells were harvested for study 48 h
posttransfection.
Antibody production, affinity purification, and sources
Polyclonal antibodies against IST1 and CHMP2A were raised against pure 
recombinant IST1 and CHMP2A in New Zealand White Rabbits (Covance, 
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Inc.)25,56. Anti-GAPDH (Millipore MAB374) and Anti-	
	 !""#	
were both commercially available monoclonal antibodies. 
The IST1 antibody was affinity purified to decrease background staining.  
Purified recombinant IST1 (10 µg) was immobilized on a sepharose column (GE 
Healthcare 17-0716-01) by amine coupling following manufacturer’s 
recommendations.  Antibody-containing serum was heat inactivated (30 min 56º 
C), diluted 1:5 in binding buffer (20 mM HEPES-buffered saline, pH 7.2), and 
applied to the column.  The column was washed with 5–10 column volumes of 
binding buffer, and the protein was eluted with elution buffer (2% glycine, 150 
mM NaCl, pH 3) and collected in 500 µl fractions directly into 500 µl aliquots of 
2X antibody storage buffer (50 mM HEPES pH 7.2, 150 mM NaCl, and 3% BSA).
Fractions containing the affinity-purified IST1 antibody were identified by 
immunoblotting against purified IST1.   
Western blotting
HeLa cells (from single wells of a 6-well plate, 1x106 cells/well) transfected 
with siRNA or transduced with shRNA were collected into 60 µl lysis buffer (50 
mM HEPES pH 7.2, 150 mM NaCl, 1% triton X-100, 5 mM 2-mercaptoethanol, 
and a 1:200 dilution of mammalian protease inhibitor) and incubated on ice for 20 
min to lyse the cells.  The samples were diluted 1:1 into 2x SDS loading buffer 
(4% SDS, 0.1M Tris-HCL, 20% glycerol, 3.73 mM bromophenol blue, 5% 2-
mercaptoethanol), and boiled for 5 min. Protein lysates were then 
electrophoresed (12.5% polyacrylamide) and transferred to PVDF membranes
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(Millipore IPFL00010).  Protein-containing PVDF membranes were incubated for
1 h in 5% milk in Tris-buffered saline (TBS; 135 mM NaCl, 2.5 mM KCl, 25 mM 
Tris base, pH 7.4) and then incubated overnight with primary antibody (1:500 
affinity-purified IST1, 1:500 CHMP2A, or 1:10,000 GAPDH) diluted in 5% milk in 
TBS with .1% Tween (TBS-T).  The membrane was then washed in TBS-T and 
incubated for 1 h with secondary antibodies diluted in 5% milk in TBS-T
(1:10,000 IRDye 700DX, 611-730-127 VWR International and 1:10,000 Rockland 
IRDye 800, 610-132-121 VWR International).  Membranes were washed again in 
TBS-T and visualized using the Odyssey Infrared Imaging System (LI-COR).
Immunofluorescence imaging
HeLa cell lines were seeded onto glass cover slips (12-well plates, 3X104 
cells/well) 24 h prior to siRNA transfection with siRNA transfection performed as 
described above. Forty-eight hours posttransfection, the cells were washed with 
PBS, incubated in 4% paraformaldehyde (37º C) or methanol (4º C) for 10 min, 
and washed twice more with PBS.  These fixed cells were then incubated for 10–
30 min in block/permeabilization buffer (BP buffer, PBS, 0.01% Triton X-100, 3% 
BSA).  
Fixed, permeabilized cells were incubated for at least 2 h in primary 
antibody diluted in BP buffer (IST1 1:500; 	!!$$$$).  Samples were 
washed twice with wash buffer (PBS, 0.01% Triton X-100), incubated in 
secondary antibody diluted in BP buffer for 1 h (1:1,000 Alexa Fluor 488, A21206 
Invitrogen), and then incubated in SYTOX Green (Invitrogen S7020; 1 µM in 
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wash buffer) or Hoechst (Invitrogen H21492, 1 µM in wash buffer) to stain the 
nuclei (10 min 23ºC).  The fixed and stained cells were washed twice more with 
wash buffer, and the cover slips were mounted on slides and visualized in
Fluoromount G mount solution (Fisher Scientific 0100-01).  
Fluorescence microscopic quantification of abscission failure
Cells were prepared for immunofluorescence as described above and the 
fraction of cells with visible intercellular bridges or multiple nuclei was quantified 
(cells with visible intercellular bridges or multiple nuclei divided by total cells 
counted). The increase in the fraction of cells with visible intercellular bridges or 
multiple nuclei as compared to control was defined as the fraction of cells that 
failed in abscission.  Three groups of 100 cells were counted and averaged to 
obtain error bars for each experiment, and the entire experiment was repeated 
three times.   
DNA content assays for abscission failure
Abscission failure was also scored by analyzing the DNA contents of HeLa
cells transduced with the pU6-CMV vectors (pU6.CON-CMV, pU6.CHMP2A-
CMV, pU6.CON-CMV.CHMP2A, pU6.CHMP2A-CMV.CHMP2A, pU6.CON-
CMV.CHMP2A3M, and pU6.CHMP2A-CMV.CHMP2A3M). Each pU6-CMV 
expression vector (5 µg) was cotransfected (PEI) into 293T cells (24 h after 
seeding, initial density of 2x106 in a 10 cm dish) together with the 
pCMVdeltaR8.91 (5 µg) and pMD.G (2 µg) vectors.  The media was changed 12
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h posttransfection. The virus-containing supernatant was collected 36 h 
posttransfection, filtered (.45 µm filter), frozen, and stored at 80º C in 1 ml 
aliquots. 
HeLa cells were seeded (initial density of 2x105 cells/well) in 6-well plates
and transduced with 1:1 mixture of 1 ml of virus-containing supernatant from the
frozen stock and 1ml of fresh media. The media was changed 12 h 
posttransduction, and the cells were reseeded 48 h posttransduction into 6-well 
plates (initial density of 4x105 cells/well).  
After an additional 48 h, cells from each well were individually treated with 
trypsin, washed, and incubated in 0.4 ml of propidium iodide solution (50 µg/ml of 
propidium iodide, in PBS, 0.01% Triton X-100, .25 mg RNase/ml, at 4ºC for 30 
min). 104 cells were analyzed for propidium iodide fluorescence using the 
FACScanII flow cytometer, and peak volumes were analyzed using Modfit LT 
software (version 2.0) to determine the percentage of cells with 2C, 4C, and 8C 
DNA contents. An increase in the percent of cells with 4C and 8C DNA contents 
as compared to control is the fraction of cells that failed in abscission.  
Results and Discussion
IST1 depletion/rescue assay
The IST1 depletion/rescue assay was validated by showing that: 1) 
depletion of endogenous IST1 resulted in an increase of the fraction of cells with 
visible intercellular bridges or multiple nuclei and 2) expression of exogenous, 
wild-type IST1 from an siRNA-resistant construct rescued the increase of the
fraction of cells with visible intercellular bridges or multiple nuclei in cells depleted 
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of endogenous IST1.  The fraction of cells with a visible intercellular bridge or 
multiple nuclei induced by IST1 was quantified by determining the fraction of cells
that exhibited either visible intercellular bridges or multiple nuclei (Fig. 2.3). 
Treatment of HeLa cells with either of two siRNAs that targeted IST1 
(termed IST1-1 and IST1-2) efficiently depleted endogenous IST1 from HeLa 
cells as measured by western blotting (Fig. 2.3, panel 2, compare lanes 2 and 3 
to lane 1).  In both cases, IST1 depletion resulted in the fraction of cells with 
visible intercellular bridges or multiple nuclei (31% ± 4% and 36% ± 1%, 
respectively) as compared to HeLa cells treated with a control siRNA (9% ± 
0,8%, CON, Fig. 2.3, panel 1, compare lanes 2 and 3 to lane 1).  Thus, IST1 
depletion induces a measurable phenotype.  
The fraction of cells with visible intercellular bridges or multiple nuclei was 
normal in a HeLa cell line depleted of endogenous IST1 and expressing siRNA-
resistant YFP-IST1, demonstrating that exogenous expressed IST1 can 
functionally replace the endogenous protein.  To perform these experiments, I 
created a stable HeLa cell line expressing an siRNA-resistant YFP-IST1 
construct.  As shown in Fig. 2.3, these cells expressed both endogenous IST1 
and YFP-IST1, as assayed by western blotting with an anti-IST1 antibody (Fig.
2.3, panel 2, lane 4).  Expression of the YFP-IST1 protein did not increase the 
fraction of cells with visible intercellular bridges or multiple nuclei (Fig. 2.3, panel 
1, compare lanes 1 and 4, 9% ± 0.8% and 9% ± 3%, respectively).  As expected, 
treatment with IST-1 siRNA depleted the endogenous IST1 protein but did not 
affect the levels of the siRNA-resistant YFP-IST1 construct (Fig. 2.3, panel 2, 
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compare lanes 4 and 5).  Importantly, this treatment did not significantly increase 
the fraction of cells with visible intercellular bridges or multiple nuclei as 
compared to treatment with a control siRNA (Fig. 2.3, panel 1, compare lanes 1 
and 5, 9% ± 3% and 11% ± 1%, respectively).  As expected, however, treatment 
with IST1-2 siRNA depleted both endogenous IST1 and exogenous YFP-IST1
and induced a dramatic increase in the fraction of cells with visible intercellular 
bridges or multiple nuclei (Fig. 2.3, panel 1, compare lanes 1 and 6, 9% ± 3% 
and 41% ± 0.4%, respectively).  I therefore conclude that the increase in the 
fraction of cells with visible intercellular bridges or multiple nuclei induced by 
treatment with either of the IST1 siRNAs is specifically caused by IST1 depletion
and that the siRNA-resistant YFP-IST1 constructs can rescue the increase in the 
fraction of cells with visible intercellular bridges or multiple nuclei induced by
depletion of endogenous IST1.
CHMP2A depletion/rescue assay
As with the IST1 depletion/rescue assay, the CHMP2A depletion/rescue 
assay was validated by showing that: 1) depletion of endogenous CHMP2A 
resulted in an increase in the fraction of cells with 4 and 8C DNA contents and 2) 
wild-type CHMP2A from an shRNA-resistant construct rescued the increase in 
the fraction of cells with 4 and 8C DNA contents in cells depleted of CHMP2A. In 
this assay, the percentage of cells with 4 and 8C DNA contents were quantified 
using DNA content analyses (Fig. 2.4). 
Treatment of HeLa cells with a CHMP2A shRNA depleted endogenous 
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CHMP2A as determined by western blotting (Fig. 2.4, panel 2, lane 2).  CHMP2A 
depletion induced an increase in the fraction of cells with 4 and 8C DNA contents 
as compared to HeLa cells treated with a control shRNA (CON; Fig. 2.4, panel 1, 
compare lanes 1 and 2, 14% ± 0.5% 4C, 0.5% ± 0.2% 8C vs. 22% ± 4% 4C, 6% 
± 2% 8C, respectively).  Hence, CHMP2A depletion significantly increases the 
fraction of cells with 4 and 8C DNA contents, producing a measurable 
phenotype. 
The fraction of cells with 4 and 8C DNA contents was normal in HeLa cells 
depleted of endogenous CHMP2A and expressing shRNA-resistant CHMP2A, 
demonstrating that exogenous CHMP2A can functionally replace endogenous 
protein.  To perform these experiments, I created transduction vectors that 
expressed a CHMP2A or control (CON) shRNA and an shRNA-resistant 
CHMP2A construct (pU6.CHMP2A_CMV_CHMP2A and pU6.CON_CMV
.CHMP2A).  As shown in Fig. 2.4, HeLa cells expressing both endogenous and 
exogenous CHMP2A did not show an increase in the fraction of cells with 4 and 
8C DNA contents (compare lanes 1 and 3, 14% ± 0.5% 4C, 0.5% ± 0.2% 8C vs.
13% ± 2% 4C, .8% ± 0.4% 8C, respectively).  Importantly, HeLa cells expressing 
exogenous CHMP2A and depleted of endogenous protein also had a normal 
fraction of cells with 4 and 8C DNA contents (Fig. 2.4, compare lanes 1 and 4, 
14% ± 0.4% 4C, 0.7% ± 0.2% 8C vs. 12% ± 1% 4C, 0.7% ± 0.2% 8C, 
respectively).  These data confirm that CHMP2A depletion induces an increase in 
the fraction of cells with 4 and 8C DNA contents and that exogenous CHMP2A 
can functionally replace the endogenous protein. 
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Functional importance of the basic patch on ESCRT-III helix one
The IST1 and CHMP2A depletion/rescue assays were used to test the 
model for membrane binding proposed by Weissenhorn and colleagues, and to 
provide a “proof of principle” that these assays could be used in genetic analyses 
of IST1 and CHMP2A abscission functions24.  The model for ESCRT-III
membrane binding proposed by Weissenhorn and colleagues predicts that the 
exposed basic patches on the first alpha helix of IST1 and CHMP2A mediate 
membrane binding24.  To test this model, I generated siRNA-resistant expression 
constructs with the following basic-patch mutations: YFP-IST1 3M (containing the 
helix one basic patch mutations R16E, R27E, and K38E) and CHMP2A 3M 
(containing the helix one basic patch mutations R16E, R27E, and K42E).  As 
illustrated in Fig. 2.5, these charge reversals eliminated the basic character of the 
helix one patches, and were therefore expected to abrogate any ionic membrane 
interactions mediated by these patches. The mutant ESCRT-III protein IST1 
lacking the basic patches failed to function in abscission while the mutant 
CHMP2A protein function in abscission was ambiguous, demonstrating the 
importance of this patch for IST1 function in abscission. 
To test the functionality of the mutant YFP-IST1 3M protein, I generated a 
HeLa cell line that expressed this protein at approximately the same level as the 
wild-type YFP-IST1 control line (Fig. 2.3, panel 2, compare lanes 4 and 7).  This 
cell line did not show an increase in the fraction of cells with visible intercellular 
bridges or multiple nuclei, demonstrating that the mutant YFP-IST1 3M protein 
did not dominantly inhibit endogenous IST1 protein function (panel 1, compare 
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lane 7 to lanes 4 and 1; 8% ± 1%, 9% ± 3%, and 9% ± 0.8%, respectively).  
However, depletion of endogenous IST1 with the IST1-1 siRNA resulted in a 
dramatic increase in the fraction of cells with visible intercellular bridges or 
multiple nuclei (Fig. 2.3, lane 8, 39% ± 6%).  This treatment did not alter 
exogenous YFP-IST1 3M protein levels, and I therefore conclude that, unlike 
wild-type IST1, the mutant YFP-IST1 3M protein cannot rescue the increase in 
the fraction of cells with visible intercellular bridges or multiple nuclei induced by 
depletion of endogenous IST1.  As expected, treatment with IST1-2 siRNA 
depleted both endogenous IST1 and exogenous YFP-IST1 3M, resulting in an 
even greater increase in the fraction of cells with visible intercellular bridges or 
multiple nuclei (Fig. 2.3, lane 9, 40% ± 1%).  
To determine the functionality of the CHMP2A 3M protein, I created 
transduction vectors that expressed control shRNA (CON) or an shRNA that 
targeted CHMP2A, as well as an shRNA-resistant CHMP2A 3M construct.  As 
shown in Fig. 2.4, HeLa cell expression of CHMP2A 3M did not cause and 
increase in the fraction of cells with 4 and 8C DNA contents (compare lane 1 to 
lane 5, 14% ± 0.5% 4C, 0.5% ± 0.2% 8C, vs. 14% ± 2% 4C, 0.5% ± 0.1% 8C, 
respectively).  However, HeLa cells that expressed CHMP2A 3M and were 
depleted of endogenous CHMP2A exhibited a significant increase in the fraction 
of cells with 4 and 8C DNA contents (Fig. 2.4, compare lane 1 to lane 6, 14% ±




In summary, I have developed and validated IST1 and CHMP2A 
depletion/rescue assays and shown that these assays can be used in genetic 
analyses of IST1 and CHMP2A function in abscission.  My data also confirm the 
functional importance of the basic patches on helix one of IST1 consistent with 
the ESCRT-III membrane-binding model proposed by Weissenhorn and 
colleagues; however, these experiments did not specifically implicate these 
residues in membrane binding24.  My attempts to confirm the importance of the 
basic patches of IST1 in membrane were inconclusive.  Mutant IST1 protein 
lacking the basic patches failed to localize to the intercellular bridge, suggesting 
that these mutations produced a transport/localization defect (data not shown). 
The functional importance of the CHMP2A basic patches is also ambiguous in 
the present work.  The ability of CHMP2A 3M to functionally replace endogenous 
protein was dependent upon viral titer used in the transduction, where high viral 
titers indicated that CHMP2A 3M partially functionally replaced endogenous 
protein, and low viral titers suggested that CHMP2A 3M did not functionally 
replace endogenous protein (data from all titers were included in Fig. 2.4).
Possible reasons for this include mutation of nonessential basic residues or 
mutation of too few basic residues in CHMP2A 3M.  Importantly, this 
phenomenon was unique to the CHMP2A 3M construct as all other constructs 
showed no differences due to viral titer. 
In the future, these assays can be applied to address other aspects of
IST1 and CHMP2A functions in abscission.  Important questions in this regard 
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include defining the protein:protein interactions that support IST1 and CHMP2A 
filament formation and analyzing the features that allow these filaments to form 




Figure 2.1: IST1 forms rings and cones within the intercellular bridge 
(images provided by Leremy Colf). (A) IST1 localizes to the intercellular bridge.  
Confocal fluorescence microscopic image of two nascent daughter cells 
connected by an intercellular bridge 
%&'(#)		*-tubulin is stained green, IST1 
is stained red, and DNA is stained blue.  (B) D-storm super-resolution 
fluorescence microscopic images showing that IST1 forms rings (top two 
panels) and cones (bottom two panels) within the intercellular bridge. *-tubulin 
is stained green and IST1 is stained red.  
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Figure 2.2: Purified IST1NTD forms helices that can deform liposomes from 
within the lumen and can also form spiraling filaments or concentric rings 
(images provided by John McCullough and Adam Frost). (A) Cryo-electron 
microscopic image of IST1:lipid tubes extruding from the lumen of a liposome.
Note that the IST1 helices bind to the inner leaflet of the liposome bilayer. (B) 
2-D class averages of helical IST1:lipid tubes, demonstrating that IST1 forms a
lattice on the lumenal side of the lipid bilayer.  (C) Image representing IST1:lipid 
tubes showing helical IST1 filaments. Note that the IST1 helix shown at the 
bottom of the tube extends the length of the tube (not shown).  (D) Negatively
stained electron microscopic image of an IST1:lipid tube and adjacent IST1 
assemblies.  Inset: low-pass filtered, local contrast-enhanced image of IST1 
filaments forming concentric rings or spirals. (E) Image representing IST1 
filaments forming concentric rings or spirals. 
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Figure 2.3: IST1 is required for HeLa cell abscission, and IST1 
function(s) require basic residues of the N-terminal helix. Panel 1 shows 
the percentage of cells in each sample with abscission defects.  Error bars 
show standard deviations from four experiments except in lanes 3, 6, and 9 in 
which the error bar represents a range from two experiments.  P-values less 
than .005 (*), and less than .0005 (**) are indicated (compared to the each cell 
type control). The HeLa cell type being tested is indicated above the 
appropriate columns in the graph.  Samples were treated with the siRNA listed 
directly below the x-axis.  Panel 2 is a representative western blot (anti-IST1) 
showing the levels of endogenous IST1 and exogenous YFP-IST1 protein in 
each sample.  Panel 3 (anti-GAPDH) shows the levels of the GAPDH loading 
control in each sample.  
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Figure 2.4: CHMP2A is required for HeLa cell abscission, and CHMP2A 
function(s) requires the basic residues of the N-terminal helix. Panel 1 
shows the percentages of cells with 4C (orange) and 8C (red) DNA content (a 
measure of abscission failure).  Error bars show standard deviations calculated 
from six experiments.  P-values less than .005 (*) and less than .0005 (**) are 
indicated.  The shRNA and exogenous, shRNA-resistant protein expressed in 
each sample are listed below the x-axis. Panel 2 is a representative western 
blot (anti-CHMP2A) showing protein levels in each sample.  Panel 3 is a western 
blot (anti-GAPDH) showing levels of the GAPDH loading control in each sample. 
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Figure 2.5: Putative membrane binding surfaces of CHMP3, IST1, and 
CHMP2A. The figure shows ribbon diagrams (row 1), space-filling models 
(row 2), and electrostatic maps of the helix 1 surface (row 3), with basic 
regions in blue, acidic regions in red, and neutral regions in white. Basic 
residues that were mutated to make the CHMP3 5M, IST 3M, and CHMP2A 
3M constructs are colored blue in rows 1 and 2, and circled in red in row 324. 
Helix 1 is located at the bottom of the structures in row 1, and oriented 
toward the viewer in rows 2 and 3.  The PDB numbers for the structures 
used are: 2DG5 (CHMP3) and 3FRR (IST1).  A CHMP2A homology model 
was created using the PHYRE protein fold recognition server (http://www.sbg
.bio.ic.ac.uk/~phyre/, provided by Heidi Schubert). 
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